Results 321 to 330 of about 5,634,975 (396)
Involvement of everolimus‑induced ABCB1 downregulation in drug‑drug interactions. [PDF]
Nakayama Y, Ino A, Yamamoto K, Takara K.
europepmc +1 more source
Understanding the Drug-Drug Interaction
openaire +2 more sources
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan +6 more
wiley +1 more source
Improving the Working Models for Drug-Drug Interactions: Impact on Preclinical and Clinical Drug Development. [PDF]
Nguyen J +6 more
europepmc +1 more source
Abstract The gut microbiota plays a pivotal role in maintaining host metabolic homeostasis and overall physiological functions. Shenling Baizhu San (SLBZS), a time‐honored classical prescription for tonifying Qi, strengthening the spleen, removing dampness, and arresting diarrhea, has shown broad clinical efficacy in digestive disorders.
Jinlan Di, Xiaochun Zhang
wiley +1 more source
Real-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China. [PDF]
Guo H +6 more
europepmc +1 more source
Long‐Term Temporal Profile of Motor Recovery After Intracerebral Hemorrhage
ABSTRACT Objective Limited data is available to describe the temporal profile of long‐term recovery over 1 year after the stroke in patients with spontaneous intracerebral hemorrhage (ICH). Methods A registered multicentral cohort was conducted to consecutively include non‐herniated supratentorial ICH patients from November 2013 to January 2023 ...
Yan Zheng +24 more
wiley +1 more source
Grace periods and exposure misclassification in self-controlled case-series studies of drug-drug interactions. [PDF]
Zhang H +4 more
europepmc +1 more source
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia +20 more
wiley +1 more source

